eCite Digital Repository

A budget impact analysis of iron polymaltose and ferric carboxymaltose infusions


Lim, CK and Connolly, M and Mirkazemi, C, A budget impact analysis of iron polymaltose and ferric carboxymaltose infusions, International Journal of Clinical Pharmacy, 44 pp. 110-117. ISSN 2210-7703 (2022) [Refereed Article]

Copyright Statement

2021 The Author(s), under exclusive licence to Springer Nature Switzerland AG

DOI: doi:10.1007/s11096-021-01320-4


Background: In Australia, iron deficiency anaemia can be managed by ferric carboxymaltose, and iron polymaltose given via either a traditional slow or new rapid infusion protocol. These differ in their manufacturing, administration, and monitoring requirements, with unknown associated costs. Aim To compare the direct costs of iron infusions used in Australia; and explore potential savings associated with increased uptake of the least-expensive option at a local hospital.

Method: A time-motion method was used to determine the labour and consumables associated with each infusion protocol. Secondly, a frequency analysis identified the most common iron infusion doses prescribed at the study site. The total direct costs per protocol were compared at these doses and then the potential savings from switching to the lowest-costing of these protocols where possible were explored.

Results: The most common doses were 0.5 g, 1 g, 1.5 g and 2 g. At these dose points, ferric carboxymaltose infusions are the least expensive, but only if national health subsidies are applied. In cases where they do not apply, iron polymaltose prepared from ampoules and infused using the rapid protocol ('Iron Polymaltose Ampoules Rapid') is the least expensive. Switching all applicable ferric carboxymaltose infusions and iron polymaltose infusions administered using the slow infusion protocol to Iron Polymaltose Ampoules Rapid is projected to yield up to $12,000 worth of savings annually.

Conclusions: Increased use of the Iron Polymaltose Ampoules Rapid protocol when government-subsidised options are not available is projected to have cost-saving outcomes. Investigation of implementation strategies to increase the use of this protocol are warranted.

Item Details

Item Type:Refereed Article
Keywords:budget impact analysis, iron infusion, iron polymaltose, ferric carboxymaltose
Research Division:Biomedical and Clinical Sciences
Research Group:Pharmacology and pharmaceutical sciences
Research Field:Clinical pharmacy and pharmacy practice
Objective Division:Health
Objective Group:Provision of health and support services
Objective Field:Inpatient hospital care
UTAS Author:Lim, CK (Mr Chuin Khai Lim)
UTAS Author:Connolly, M (Mr Michael Connolly)
UTAS Author:Mirkazemi, C (Dr Corinne Mirkazemi)
ID Code:150791
Year Published:2022
Deposited By:Pharmacy
Deposited On:2022-06-30
Last Modified:2022-10-14

Repository Staff Only: item control page